lipostat 20mg tablets
bristol myers squibb pharmaceuticals ltd. - pravastatin sodium - tablets - 20 mg - serum lipid reducing agents/cholesterol and triglyceride reducers/hmg-coa reductase inhibitors - treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate; reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet: reduction of cardiovascular mortality and morbidity in patients with a history of myocardial infarction (mi) or unstable angina pectoris and with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors; reduction of post transplantation hyperlipidaemia in patients receiving immunosuppressive therapy following solid organ transplantation
lipostat 40mg tablets
bristol myers squibb pharmaceuticals ltd. - pravastatin sodium - tablets - 40mg - serum lipid reducing agents/cholesterol and triglyceride reducers/hmg-coa reductase inhibitors - treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate; reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet; reduction of cardiovascular mortality and morbidity in patients with a history of myocardial infarction (mi) or unstable angina pectoris and with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors; reduction of post transplantation hyperlipidaemia in patients receiving immunosuppressive therapy following solid organ transplantation.
lipostat 10mg tablets
bristol myers squibb pharmaceuticals ltd. - pravastatin sodium - tablets - 10mg - serum lipid reducing agents/cholesterol and triglyceride reducers/hmg-coa reductase inhibitors - treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate; reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet; reduction of cardiovascular mortality and morbidity in patients with a history of myocardial infarction (mi) or unstable angina pectoris and with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors; reduction of post transplantation hyperlipidaemia in patients receiving immunosuppressive therapy following solid organ transplantation.
perfalgan 1g/100ml solution for infusion vials
bristol-myers squibb pharmaceuticals ltd - paracetamol - solution for infusion - 10mg/1ml
perfalgan 500mg/50ml solution for infusion vials
bristol-myers squibb pharmaceuticals ltd - paracetamol - solution for infusion - 10mg/1ml
baraclude 0.5mg tablets
bristol-myers squibb pharmaceuticals ltd - entecavir monohydrate - tablet - 500microgram
baraclude 1mg tablets
bristol-myers squibb pharmaceuticals ltd - entecavir monohydrate - tablet - 1mg
orencia 250mg powder for concentrate for solution for infusion vials
bristol-myers squibb pharmaceuticals ltd - abatacept - powder for solution for infusion - 250mg
orencia 125mg1ml solution for injection pre-filled syringes
bristol-myers squibb pharmaceuticals ltd - abatacept - solution for injection - 125mg/1ml
daklinza 30mg tablets
bristol-myers squibb pharmaceuticals ltd - daclatasvir dihydrochloride - tablet - 30mg